Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans

Drug Metabolism and Disposition

Volumn 34, Issue 1, 2006, Pages 69-74

  Gurley, Bill J ^a,b   Barone, Gary W ^a   Williams, D Keith ^b   Carrier, Julie ^c   Breen, Philip ^a   Yates, C Ryan ^d   Song, Peng Fei ^d   Hubbard, Martha A ^a   Tong, Yudong ^a   Cheboyina, Sreekhar ^e  

^a Department of Pharmaceutical Sciences ^*

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c 3202 Bell Engineering Center   (United States)

^d UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^e UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIMICIFUGA RACEMOSA EXTRACT; CLARITHROMYCIN; DIGOXIN; GLYCOPROTEIN P; RIFAMPICIN; SILYBUM MARIANUM EXTRACT;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHEMOLUMINESCENCE; CIMICIFUGA RACEMOSA; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DIGOXIN BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN EXPERIMENT; IMMUNOASSAY; IN VIVO STUDY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; RANDOMIZED CONTROLLED TRIAL; SILYBUM MARIANUM; STATISTICAL SIGNIFICANCE;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; CIMICIFUGA; CLARITHROMYCIN; DIETARY SUPPLEMENTS; DIGOXIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENES, MDR; HALF-LIFE; HAPLOTYPES; HERB-DRUG INTERACTIONS; HUMANS; MALE; MILK THISTLE; PLANT PREPARATIONS; RIFAMPIN;

CIMICIFUGA DAHURICA; CIMICIFUGA RACEMOSA; SILYBUM; SILYBUM MARIANUM;

EID: 30044432615     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.105.006312     Document Type: Article

References (42)

1. Anonymous (2005) Disintegration and dissolution of dietary supplements, in The Pharmacopoeia of the United States Twenty-eighth Revision and the National Formulary, Twenty-third Edition, pp 2778-2779, United States Pharmacopoeia Convention, Inc., Rockville, MD.
2. Arold G, Donath F, Maurer A, Diefenbach K, Bauer S, Henneicke-von Zepelin H-H, Friede M, and Roots I (2005) No relevant interaction with alprazolam, caffeine, tolbutamide and digoxin by treatment with a low-hyperforin St John's wort extract. Planta Med 71:331-337.
3. Borrelli F, Izzo AA, and Ernst E (2003) Pharmacological effects of Cimicifuga racemosa. Life Sci 73:1215-1229.
4. Brazier NC and Levine MAH (2003) Drug-herb interactions among commonly used conventional medicines: a compendium for health care professionals. Am J Ther 10:163-169.
5. Cohen J (1988) Statistical Power Analysis for the Behavioral Sciences, 2nd ed, pp 19-42. Lawrence Erlbaum Associates Publishers, Hillsdale, NJ.
6. [CUCAMAP] Committee on the Use of Complementary and Alternative Medicine by the American Public (2005) Complementary and Alternative Medicine in the United States. The National Academies Press, Washington, DC.
7. DiCenzo R, Shelton M, Jordan K, Koval C, Forrest A, Reichman R, and Morse G (2003) Coadministration of milk thistle and indinavir in healthy subjects. Pharmacotherapy 23:866-870.
8. Dresser GK, Schwartz UI, Wilkinson GR, and Kim RB (2003) Coordinate induction of both cytochrome P4503A and MDR1 by St. John's wort in healthy subjects. Clin Pharmacol Ther 73:41-50.
9. Dürr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ, and Fattinger K (2000) St. John's wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 68:598-604.
10. Foster BC, Vandenhoek S, Hana J, Krantis A, Akhtar MH, Bryan M, Budzinski JW, Ramputh A, and Arnason JT (2003) In vitro inhibition of human cytochrome P450-mediated metabolism of marker substrates by natural products. Phytomedicine 10:334-342.
11. Ganzera M, Bedir E, and Khan IA (2000) Separation of Cimicifuga racemosa triterpene glycosides by evaporative light scattering detection. Chromatographia 52:301-304.
12. Gorski JC, Huang S-M, Pinto A, Hamman MA, Hilligoss JK, Zaheer NA, Desai M, Miller M, and Hall SD (2004) The effect of Echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther 75:89-100.
13. Greiner B, Eichelbaum M, Fritz P, Kreichgauer H-P, von Richter O, Zundler J, and Kroemer HK (1999) The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Investig 104:147-153.
14. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry B, Carrier J, Khan IA, Edwards DJ, and Shah A (2004) In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, saw palmetto. Clin Pharmacol Ther 76:428-440.
15. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y, and Ang CYW (2002) Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin Pharmacol Ther 72:276-287.
16. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y, and Ang CYW (2005a) Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St. John's wort, garlic oil, panax ginseng and ginkgo biloba. Drugs Aging 22:525-539.
17. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Khan IA, and Shah A (2005b) In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1 and 3A4/5 phenotypes. Clin Pharmacol Ther 77:415-426.
18. Johne A, Brockmoller J, Bauer S, Maurer A, Langheinrich M, and Roots I (1999) Pharmacokinetic interaction of digoxin with an herbal extract from St. John's wort (Hypericum perforatum). Clin Pharmacol Ther 66:338-345.
19. Johne A, Kopke K, Gerloff T, Mai I, Rietbrock S, Meisel C, Hoffmeyer S, Kerb R, Fromm MF, Brinkmann U, et al. (2002) Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther 72:584-594.
20. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, and Mitchell AA (2002) Recent patterns of medication use in the ambulatory adult population of the United States. J Am Med Assoc 287:337-344.
21. Kim YC, Kim EJ, Lee ED, Kim JH, Jang SW, Kim YG, Kwon JW, Kim WB, and Lee MG (2003) Comparative bioavailability of silibinin in healthy male volunteers. Int J Clin Pharmacol Ther 41:593-596.
22. Kurata Y, Iciri I, Kimura M, Morita T, Irie S, Urae A, Ohdo S, Ohtani H, Sawada Y, Higuchi S, et al. (2002) Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther 72:209-219.
23. Li F-Q and Hu J-H (2004) Improvement of the dissolution rate of silymarin by means of solid dispersions. Chem Pharm Bull 52:972-973.
24. Maitrejean M, Comte G, Barron D, El Kirat K, Conseil G, and Di Pietro A (2000) The flavanolignan silybin and its hemisynthetic derivatives, a novel series of potential modulators of P-glycoprotein. Bioorg Med Chem Lett 10:157-160.
25. Mills E, Wilson K, Clarke M, Foster B, Walker S, Rachlis B, DeGroot N, Montori VM, Gold W, Phillips E, et al. (2005) Milk thistle and indinavir: a randomized controlled pharmacokinetics study and meta analysis. Eur J Clin Pharmacol 61:1-7.
26. Patel J, Buddha B, Dey S, Pal D, and Mitra AK (2004) In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity. Am J Ther 11:262-277.
27. Piscitelli SC, Formentini E, Burstein AH, Alfaro R, Jagannatha S, and Falloon J (2002) Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers. Pharmacotherapy 22:551-556.
28. Rajnarayana K, Reddy MS, Vidyasagar, and Krishna DR (2004) Study on the influence of silymarin pretreatment on metabolism and disposition of metronidazole. Arzneim-Forsch 54:109-113.
29. Rengelshausen J, Goggelmann C, Burhenne J, Riedel K-D, Ludwig J, Weiss J, Mikus G, Walter-Sack I, and Haefeli WE (2003) Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction. Br J Clin Pharmacol 56:32-38.
30. Saller R, Meier R, and Brignoli R (2001) The use of silymarin in the treatment of liver diseases. Drugs 61:2035-2063.
31. Savio D, Harrasser PC, and Basso G (1998) Softgel capsule technology as an enhancer device for the absorption of natural principles in humans: a bioavailability cross-over randomized study on silybin. Arzneim-Forsch 48:1104-1106.
32. Schandalik R, Gatti G, and Perucca E (1992) Pharmacokinetics of silybin in bile following administration of silipide and silymarin in cholecystectomy patients. Arzneim-Forsch 42:964-968.
33. Schulz H-U, Schurer M, Krumbiegel G, Wachter W, Weyhenmeyer R, and Seidel G (1995) Investigation of dissolution and bioequivalence of silymarin products. Arzneim-Forsch 45:61-64.
34. Song P, Shen L, Meibohm B, Gaber AO, Honaker MR, Kotb M, and Yates CR (2002) Detection of MDR1 single nucleotide polymorphisms C3435T and G2677T using real-time polymerase chain reaction: MDR1 single nucleotide polymorphism genotyping assay. AAPS Pharm Sci 4(4) article 29 (http://www.aapspharmsci.org).
35. Strandell J, Neil A, and Carlin G (2004) An approach to the in vitro evaluation of potential for cytochrome P450 enzyme inhibition from herbals and other natural remedies. Phytomedicine 11:98-104.
36. Sugimoto K, Ohmori M, Tsuruoka S, Nishiki K, Kawaguchi A, Harada K, Arakawa M, Sakamoto K, Masada M, Miyamori I, et al. (2001) Different effects of St. John's wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther 70:518-524.
37. Wallace SN, Carrier DJ, and Clausen EC (2003) Extraction of nutraceuticals from milk thistle. Appl Biochem Biotech 105-108:891-903.
38. Wentworth JM, Agostini M, Love J, Schwabe JW, and Chatterjee VKK (2000) St. John's wort, a herbal antidepressant, activates the steroid X receptor. J Endocrinol 166:R11-R16.
39. Xie R, Tan LH, Polasek EC, Hong C, Teillol-Foo M, Gordi T, Sharma A, Nickens DJ, Arakawa T, Knuth DW, et al. (2005) CYP3A and P-glycoprotein activity induction with St. John's wort in healthy volunteers from 6 ethnic populations. J Clin Pharmacol 45:352-356.
40. Zhang S and Morris ME (2003a) Effects of the flavonoids biochanin A, morin, phloretin and silymarin on P-glycoprotein-mediated transport. J Pharmacol Exp Ther 304:1258-1267.
41. Zhang S and Morris ME (2003b) Effect of the flavonoids biochanin A and silymarin on the P-glycoprotein-mediated transport of digoxin and vinblastine in human intestinal Caco-2 cells. Pharm Res (NY) 20:1184-1191.
42. Zou L, Harkey MR, and Henderson GL (2002) Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci 71:1579-1589.